Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Verweij

Showing results (61-70 of 655) with videos related to

Pageof 66
Sort By:
Cancer Treatment Reviews|January 1, 1994
Topoisomerase I inhibitors: topotecan and irenotecanG J Creemers, B Lund, J Verweij
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancerA S Planting, G Stoter, J Verweij
Biometrics|December 1, 1995
Time-dependent effects of fixed covariates in Cox regressionP J Verweij, H C van Houwelingen
Cancer Treatment Reviews|January 22, 2019
Innovation in oncology clinical trial designJ Verweij, H R Hendriks, H Zwierzina, et al.
Cancer Treatment Reviews|September 28, 2000
Farnesyl transferase inhibitors: current developments and future perspectivesF A Eskens, G Stoter, J Verweij
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 11, 2001
Clinical cancer research 2000: new agents and therapiesE. G. E. de Vries, J. Verweij
Statistics in Medicine|December 15, 1994
Penalized likelihood in Cox regressionP J Verweij, H C Van Houwelingen
European Journal of Cancer (Oxford, England : 1990)|June 3, 2006
Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all?M J A de Jonge, J Verweij
European Journal of Cancer (Oxford, England : 1990)|April 18, 2006
RECIST revisited: a review of validation studies on tumour assessmentP Therasse, E A Eisenhauer, J Verweij
Cancer Treatment Reviews|September 1, 1995
Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effectsL C Pronk, G Stoter, J Verweij
Pageof 66

Showing results (61-70 of 655) with videos related to

Sort By:
Pageof 66
Cancer Treatment Reviews|January 1, 1994
Topoisomerase I inhibitors: topotecan and irenotecanG J Creemers, B Lund, J Verweij
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancerA S Planting, G Stoter, J Verweij
Biometrics|December 1, 1995
Time-dependent effects of fixed covariates in Cox regressionP J Verweij, H C van Houwelingen
Cancer Treatment Reviews|January 22, 2019
Innovation in oncology clinical trial designJ Verweij, H R Hendriks, H Zwierzina, et al.
Cancer Treatment Reviews|September 28, 2000
Farnesyl transferase inhibitors: current developments and future perspectivesF A Eskens, G Stoter, J Verweij
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 11, 2001
Clinical cancer research 2000: new agents and therapiesE. G. E. de Vries, J. Verweij
Statistics in Medicine|December 15, 1994
Penalized likelihood in Cox regressionP J Verweij, H C Van Houwelingen
European Journal of Cancer (Oxford, England : 1990)|June 3, 2006
Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all?M J A de Jonge, J Verweij
European Journal of Cancer (Oxford, England : 1990)|April 18, 2006
RECIST revisited: a review of validation studies on tumour assessmentP Therasse, E A Eisenhauer, J Verweij
Cancer Treatment Reviews|September 1, 1995
Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effectsL C Pronk, G Stoter, J Verweij
Pageof 66